Abeona Therapeutics (ABEO) director Form 3 lists no stock trades

Rhea-AI Filing Summary

Abeona Therapeutics Inc. insider data show that Keith A. Goldan is a reporting person serving as a director. The Form 3 insider filing excerpt lists no buy, sell, acquisition, or disposition transactions and shows no derivative positions or holding entries in the provided data.

Key Figures

Buy transactions: 0 transactions Sell transactions: 0 transactions Derivative exercises: 0 transactions +1 more

4 metrics

Buy transactions 0 transactions Form 3 transactionSummary buyCount

Sell transactions 0 transactions Form 3 transactionSummary sellCount

Derivative exercises 0 transactions Form 3 transactionSummary exerciseCount

Net buy/sell direction neutral Form 3 transactionSummary netBuySellDirection

Key Terms

Form 3, insider filing, reporting person

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

insider filing regulatory

"INSIDER FILING DATA (Form 3)"

reporting person regulatory

""reportingPersons": [ { "name": "Goldan Keith A.""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Goldan Keith A.

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OHIO 44103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/01/2026

3. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Joseph Vazzano, Attorney-in-Fact	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Abeona Therapeutics (ABEO) Form 3 filing show for Keith A. Goldan?

The Form 3 insider data identify Keith A. Goldan as a director and reporting person for Abeona Therapeutics Inc. The excerpt shows no reported buy, sell, acquisition, or disposition transactions and no derivative positions in the summarized fields.

Are there any stock purchases or sales reported for ABEO director Keith A. Goldan?

No transactions are reported for Keith A. Goldan in this Form 3 excerpt. The transaction summary lists zero buys, zero sells, zero derivative exercises, and no gifts, tax withholding, or restructuring entries tied to Abeona Therapeutics Inc. shares.

Does the Abeona Therapeutics Form 3 show any derivative securities for Keith A. Goldan?

The provided Form 3 data show an empty derivativeSummary and zero derivativeTransactionCount. This indicates no derivative securities transactions, such as options or similar instruments, are reported for Keith A. Goldan in this specific excerpt.

What does the transaction summary indicate in the ABEO Form 3 insider data?

The transaction summary shows zero buy, sell, acquire, and dispose counts, with netBuySellDirection marked as neutral. It also records zero exercise, gift, tax withholding, and restructuring transactions for Keith A. Goldan related to Abeona Therapeutics Inc. stock.

Does the Abeona Therapeutics (ABEO) Form 3 excerpt disclose current share holdings?

The excerpt indicates holdingEntries as zero, so it does not present specific share holdings for Keith A. Goldan. It focuses on his status as a reporting person and director, with no detailed ownership line items in the visible data.